Innovation Hubs for Gene Therapies

Innovation Hubs for Gene Therapies

Manufacturing

The Hubs support academics in the clinical development of genetic treatments through the production of GMP viral vectors

About us

The Innovation Hubs for Gene Therapies aim to accelerate academic-led development of novel gene therapies throughout the UK. Set up in 2021 with £18m of funding from the independent research charity LifeArc, the Medical Research Council (MRC), and the Biotechnology and Biological Sciences Research Council (BBSRC), the Hubs will operate as a coordinated network, sharing technical skills and resources. Three new dedicated facilities have been created at King's College London, NHS Blood and Transplant in Bristol, and the University of Sheffield. The Hubs will enable academic researchers to progress novel gene therapy research into clinical trials, offering access to GMP (good manufacturing practice) facilities for clinical trials materials, alongside essential translational support and regulatory advice. These will manufacture commonly used vectors including both lentivirus and adeno-associated virus (AAV) that are needed for genetic therapy trials. A key aim is to smooth the transition between small-scale supply for early clinical trials through to larger-scale manufacture for patient trials, and beyond. These Hubs will position the UK for significant bioprocessing innovation work with the potential to radically increase yields and reduce productivity barriers in future years.

Website
www.genetherapyhubs.uk
Industry
Manufacturing
Company size
11-50 employees
Headquarters
London
Type
Government Agency
Founded
2021
Specialties
Bioprocessing, Advanced Therapies, Gene Therapies, Manufacturing, and Clinical Trials

Locations

Employees at Innovation Hubs for Gene Therapies

Updates

Similar pages